CureDuchenne Ventures invests in Entos Pharmaceuticals to support the development of a muscle-targeting therapeutic for Duchenne muscular dystrophy (DMD). The funding amount was not disclosed.
Round Type
Funding Round
EdmontonBiotechnologyHealth CareGeneticsTherapeuticsInvestors
Description
Entos Pharmaceuticals, an Edmonton-based biotech company, received an investment from CureDuchenne Ventures. The company plans to use the funds to develop a therapeutic aimed at delivering full-length dystrophin. This initiative targets the treatment of Duchenne muscular dystrophy (DMD). Entos utilizes its innovative Fusogenix PLV platform for genetic medicine delivery.
Who to call at Entos Pharmaceuticals, and when
A new round usually means Entos Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Entos Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Entos Pharmaceuticals, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Entos Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Entos Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.